Filing Details

Accession Number:
0000899243-21-028546
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-07-15 19:03:02
Reporting Period:
2021-07-13
Accepted Time:
2021-07-15 19:03:02
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1761612 Bicycle Therapeutics Plc BCYC () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1185040 Kate Bingham C/O Bicycle Therapeutics
B900, Babraham Research Campus
Cambridge X0 CB22 3AT
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Ordinary Shares Disposition 2021-07-13 588 $33.50 1,875,049 No 4 S Indirect By SV Life Sciences Fund V, L.P.
Ordinary Shares Disposition 2021-07-14 43,378 $34.01 1,831,671 No 4 S Indirect By SV Life Sciences Fund V, L.P.
Ordinary Shares Disposition 2021-07-13 12 $33.50 39,625 No 4 S Indirect By SV Life Sciences Fund V Strategic Partners, L.P.
Ordinary Shares Disposition 2021-07-14 917 $34.01 38,708 No 4 S Indirect By SV Life Sciences Fund V Strategic Partners, L.P.
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect By SV Life Sciences Fund V, L.P.
No 4 S Indirect By SV Life Sciences Fund V, L.P.
No 4 S Indirect By SV Life Sciences Fund V Strategic Partners, L.P.
No 4 S Indirect By SV Life Sciences Fund V Strategic Partners, L.P.
Footnotes
  1. These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.
  2. These shares were sold by SVLS V LP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein.
  3. These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, Eugene D. Hill, III and Michael J. Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.
  4. These shares were sold by SVLS V SPP pursuant to its Rule 10b5-1 Plan enacted prior to the date of the sale disclosed herein.